Article Text

Download PDFPDF
REDUCE Randomised controlled trial
Dutasteride reduces incident prostate cancer in men after negative prostate biopsy
  1. Andrew Vickers
  1. Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, USA
  1. Correspondence to Andrew Vickers
    1275 York Avenue, Box 44, New York, NY 10065, USA; vickersa{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:

Should we try to prevent prostate cancer?

In the common public perception, cancer is a bad thing: We should do all we can to cure those unlucky enough to be diagnosed with it or, better still, prevent its development in the first place. Indeed, charitable campaigns often ask us to ‘imagine a world without cancer’, ‘run cancer out of town’ or turn cancer into a big ‘zero’.

This is a perfectly understandable position for a disease such as pancreatic cancer or, say, paediatric brain tumours. Things are a little more problematic for prostate cancer. First and foremost, cancer of the prostate is almost an inevitable consequence of getting older. In one study, 80% of men (70–79 years of age) who died without a prior diagnosis of prostate cancer were found to have detectable tumours on pathologic analysis of the autopsy prostate.1 Yet prostate cancer does kill – it is the second most common cause of cancer death in males2 – …

View Full Text


  • Competing interests AV has received about $5000 in consulting fees from Glaxo Smith Kline, the manufacturers of Dutasteride.